Biotech Sector in for Third Decade of Gains: Credit Suisse

The Financialist reported that the biotech sector may be in for a third decade of gains, at least according to Credit Suisse Group AG (NYSE:CS).

As quoted in the market news:

The first era of biotech was a building phase, when companies created their first blockbuster drugs. The second, current one, has resulted in a four-year rally that reflects the sector’s transition from a cluster of one-hit wonders to mature companies with multiple blockbuster products. And now the third is just starting to emerge – Credit Suisse calls it Biotech 3.0 – that looks likely to continue to 2020 and beyond.

For the past four years, biotech stocks have been the top-performing industry in the S&P 500, and the recent outperformance has been notable: a 74 percent gain in 2013 (versus 30 percent for the S&P 500) and a 42 percent gain in 2014 (versus 11 percent). And Credit Suisse Head of Global Biotechnology Research Ravi Mehrotra expects the stocks to beat the market once again this year. ‘This multi-year outperformance has not been a simple sentiment-driven bull run, but rather a fundamental rerating of the biotech sector,’ he writes in a recent report.

Click here to read the full report from The Financialist.